EZ Cap™ Cas9 mRNA (m1Ψ): High-Stability, Capped Cas9 mRNA for Precision Genome Editing

Executive Summary: EZ Cap™ Cas9 mRNA (m1Ψ) is a 4,527-nt in vitro transcribed mRNA featuring a Cap1 structure, N1-Methylpseudo-UTP (m1Ψ) modification, and a poly(A) tail, optimized for mammalian genome editing. Cap1 capping increases translation efficiency and reduces innate immune activation in human cells (Cui et al., 2022). The m1Ψ modification further enhances mRNA stability and limits activation of pattern recognition receptors. Poly(A) tails facilitate efficient translation initiation. Proper storage and RNase-free handling are critical for maintaining reagent integrity. EZ Cap™ Cas9 mRNA (m1Ψ), by APExBIO, is intended for research use only and is not approved for diagnostic or medical applications.

Biological Rationale

CRISPR-Cas9 genome editing enables targeted DNA double-strand breaks for gene modification in mammalian cells. Constitutive Cas9 protein expression may cause off-target effects and genotoxicity (Cui et al., 2022). Delivering Cas9 as mRNA allows for temporal control and reduces persistent nuclease activity. In vitro transcribed (IVT) Cas9 mRNA is rapidly degraded after translation, reducing the risk of unwanted editing events. Cap1 capping and m1Ψ modification provide improved mRNA stability and translational efficiency while minimizing innate immune activation. These features collectively address key challenges in genome editing: specificity, efficiency, and safety (see mechanistic rationale—this article expands on the role of nuclear export and innate immune evasion).

Mechanism of Action of EZ Cap™ Cas9 mRNA (m1Ψ)

EZ Cap™ Cas9 mRNA (m1Ψ) leverages several molecular features to enable effective CRISPR-Cas9 editing:

• Cap1 Structure: Enzymatically added Cap1 (m7GpppNm) increases translation efficiency and reduces recognition by RNA sensors such as RIG-I and MDA5, compared to Cap0 structures (Cui et al., 2022).
• N1-Methylpseudo-UTP (m1Ψ) Incorporation: Substitution of UTP with m1Ψ enhances mRNA stability, reduces activation of innate immune receptors (TLR3, TLR7/8), and prolongs mRNA half-life.
• Poly(A) Tail: The polyadenylated tail (typically ≥100 nt) supports efficient translation and mRNA stability in eukaryotic cells.
• Buffer & Handling: Supplied at ~1 mg/mL in 1 mM Sodium Citrate, pH 6.4, supporting mRNA integrity.

Once transfected, the mRNA is translated in the cytoplasm to produce Cas9 protein, which complexes with guide RNA to mediate DNA cleavage. Rapid decay of mRNA ensures transient expression, reducing off-target risks. These molecular modifications collectively achieve high editing precision and low immunogenicity (see analysis; this article updates on new evidence linking cap structure to immune evasion).

Evidence & Benchmarks

• Cap1-capped, m1Ψ-modified Cas9 mRNAs exhibit significantly reduced innate immune activation compared to unmodified IVT mRNA (Cui et al., 2022).
• Poly(A) tails of 100–120 nt enhance mRNA stability and translation by protecting against deadenylation and supporting ribosome recruitment (Cui et al., 2022).
• Transient Cas9 mRNA delivery results in lower off-target editing rates than plasmid or viral vector-based Cas9 expression (Cui et al., 2022).
• Cap1 structure, generated via Vaccinia virus capping enzyme and 2'-O-methyltransferase, increases mRNA translation in mammalian cells by up to 2-fold compared to Cap0 (Cui et al., 2022).
• Use of m1Ψ-modified mRNA suppresses activation of TLR7/8 and RIG-I pathways, reducing IFN-α secretion in primary human cells (Cui et al., 2022).

Applications, Limits & Misconceptions

EZ Cap™ Cas9 mRNA (m1Ψ) is optimized for CRISPR-Cas9 genome editing in mammalian systems. Key applications include:

• Gene knockout and knock-in studies in cultured mammalian cells.
• Base and prime editing when co-delivered with appropriate guide RNAs and templates.
• Preclinical research requiring transient, high-specificity gene editing.

Related article: This article clarifies how Cap1 and m1Ψ modifications specifically reduce immune activation compared to older mRNA formats, extending previous discussions on molecular innovations.

Common Pitfalls or Misconceptions

• Direct addition of mRNA to serum-containing media without transfection reagent results in rapid degradation and poor uptake.
• Multiple freeze-thaw cycles can degrade mRNA integrity; aliquot and store at ≤ -40°C.
• Product is for research use only; not validated or licensed for diagnostic or therapeutic applications.
• Unmodified or Cap0 mRNA provides lower efficiency and higher immunogenicity in mammalian cells.
• Cas9 mRNA must be handled with RNase-free reagents to prevent degradation.

Workflow Integration & Parameters

For optimal results, EZ Cap™ Cas9 mRNA (m1Ψ) should be handled on ice, protected from RNase, and aliquoted to avoid freeze-thaw cycles. Recommended working concentration is ~1 mg/mL in 1 mM Sodium Citrate, pH 6.4. Transfection should be performed using validated reagents suitable for mRNA delivery. Do not introduce mRNA directly into serum-containing media without a compatible transfection reagent, as serum nucleases will degrade unprotected mRNA. Co-delivery with guide RNA is required for CRISPR-Cas9 activity. Use RNase-free plastics and reagents throughout. For further guidance on delivery protocols and precision editing, see this article, which offers deeper practical workflow recommendations—this article supplements by focusing on structural and immunogenicity aspects.

Conclusion & Outlook

EZ Cap™ Cas9 mRNA (m1Ψ), by APExBIO, exemplifies the next generation of capped Cas9 mRNA for genome editing, combining Cap1 structure and m1Ψ modification for high stability, efficient translation, and minimized immune activation (product page). These features enable precise and transient genome editing, reducing the risk of off-target effects and cytotoxicity. Ongoing advances in mRNA engineering and delivery will further improve the safety and efficiency of CRISPR-Cas systems in mammalian research. Researchers should continue to monitor best practices for mRNA handling, delivery, and immunogenicity screening to maximize editing outcomes.